ArisGlobal's Award-Winning AI for Pharmacovigilance
ArisGlobal, a pioneering technology company specializing in artificial intelligence within life sciences, has recently garnered the esteemed
New Product Innovation Recognition 2025 from Frost & Sullivan. This recognition emphasizes ArisGlobal's exceptional advancements in pharmacovigilance through their
MedDRA Coding Agent, the industry’s first agentic AI designed to revolutionize safety data coding, analysis, and delivery.
Launched in April 2025, the MedDRA Coding Agent quickly attracted significant interest within the industry. By employing agentic AI, it mimics human judgment in medical coding, addressing the limitations often found in conventional static rule-based systems. Unlike traditional automation tools, ArisGlobal's innovative solution dynamically interprets clinical language, selects appropriate reasoning paths, and learns from reviewer feedback to continuously enhance accuracy and transparency.
Key Features of the MedDRA Coding Agent
1.
Agentic Context Understanding: Goes beyond keywords to interpret the meaning and intent of clinical language.
2.
Continuous Learning Loop: Adapts in real time to corrections from reviewers and evolving MedDRA terminology.
3.
Explainable and Verifiable Decisions: Provides transparent justifications ensuring regulatory compliance.
4.
Multilingual and Enterprise Ready: Supports global operations, integrations, and validation requirements.
5.
Adaptive Collaboration: Escalates issues only when necessary and offers tiered, rational coding options.
This next-generation approach significantly boosts coding efficiency, reduces the requirements for manual reviews, and enhances consistency and compliance across large, global teams.
In an independent validation by Frost & Sullivan, the company noted that ArisGlobal is leading the redefinition of pharmacovigilance with context-sensitive agentic systems that offer measurable operational and compliance advantages. According to
Norazah Bachok, a Best Practices Research Analyst at Frost & Sullivan, the MedDRA Coding Agent is flexible, verifiable, and scalable for enterprises. It can achieve efficiency improvements of up to 80%, substantially relieving reviewers of burdens while maintaining uncompromised accuracy.
Jason Bryant, Senior Vice President of Product Management - AI at ArisGlobal, stated, "The MedDRA Coding Agent represents a significant leap forward in automating pharmacovigilance processes. By merging cognitive depth with our established capabilities through LifeSphere NavaX, we are transforming complex coding tasks into intelligent, adaptable workflows that yield higher accuracy and efficiency on a large scale. This innovation underscores our persistent investment in research and development as we push for greater automation throughout the safety and regulatory value chain."
In receiving Frost & Sullivan's Best Practices Recognition Awards, companies worldwide are celebrated for excellence in leadership, technological innovations, customer service, and strategic product development. The New Product Innovation Recognition is the apex award given to market players who demonstrate visionary innovations, industry-leading performance, and unparalleled customer service.
ArisGlobal stood out during Frost & Sullivan's rigorous evaluation of strategic effectiveness and implementation, showcasing a strong alignment with evolving market demands and operational excellence. This award highlights ArisGlobal’s influence on innovation, customer value, and performance standards across the industry.
About ArisGlobal
Founded in the United States, ArisGlobal is an AI-powered technology company and the inventor of LifeSphere®, which is reshaping how leading life science companies develop and introduce groundbreaking innovations. With regional offices in Europe, India, Japan, and China, ArisGlobal emphasizes the importance of technological innovation in enhancing the pharmaceutical landscape. For more updates, follow ArisGlobal on LinkedIn.
www.arisglobal.com